Tinnitus is common after cisplatin: 68% of 145 testicular cancer survivors treated with it reported tinnitus, and the drug stays in the cochlea for months to years, which helps explain why the tinnitus and hearing loss are often permanent. Cisplatin is used for testicular, ovarian, lung and several other cancers, and its numbers are specific enough to deserve their own page; ototoxic medications covers drug-related tinnitus more broadly, and gentamicin and tinnitus covers the antibiotic most often named.
How common it is
A study of 145 testicular cancer survivors who received cisplatin-based chemotherapy found 74% reported some form of ototoxicity — hearing loss and/or tinnitus — with 68% specifically reporting tinnitus and 59% reporting hearing loss (52% had both). A separate, larger study of 243 testicular cancer survivors found broadly consistent numbers: hearing loss in 56.4% and tinnitus in 60.5%. These aren't small or unusual side-effect rates — for a substantial share of patients receiving cisplatin, tinnitus is closer to an expected outcome than a rare complication.
It is dose-dependent
Research consistently identifies cumulative cisplatin dose as a significant, measurable risk factor — more total cisplatin over the course of treatment means higher ototoxicity risk. One study also found tinnitus specifically associated with age at the time of the survey and with a history of noise exposure, meaning the risk isn't uniform across all patients receiving the same treatment; some combination of dose, age, and prior noise history shapes who's more likely to be affected. Official prescribing information for cisplatin describes the ototoxicity as cumulative and potentially severe, affecting the high-frequency range (4,000–8,000 Hz) initially, sometimes progressing to affect the ability to hear normal conversational tones at higher doses.
Why this happens
Cisplatin's ototoxic mechanism is different from that of most other causes of tinnitus — it's directly toxic to cochlear hair cells, and it does not leave. A 2017 study that measured cisplatin in the cochleae of mice and of people found that most organs clear the drug over days to weeks, but the cochlea retains it for months to years after treatment, concentrated in the stria vascularis, the part of the cochlea that maintains the ionic composition of its fluid. Its effect on the inner ear isn't a temporary exposure that clears from the body the way many drugs do. This helps explain why cisplatin-related hearing loss and tinnitus are frequently permanent rather than resolving after treatment ends, unlike some of the more reversible medication-related causes.
Not just a side note — a real quality-of-life impact
A study using validated functional-impairment questionnaires (not just yes/no symptom checklists) found one in three testicular cancer survivors with hearing loss reported clinically significant functional impairment from it, and the same research noted hearing loss is independently recognized as the largest modifiable risk factor for cognitive decline and dementia in the general population — a reason the researchers specifically recommended routine audiological assessment for cisplatin-treated survivors, not just symptom management after the fact.
What this means if you're facing cisplatin treatment
This isn't a reason to avoid a cancer treatment that may be the most effective option available — that's a decision between you and your oncologist, weighing cancer treatment efficacy against a real but generally non-life-threatening side effect. What it does mean:
- Baseline and follow-up hearing tests are a reasonable thing to ask for before, during, and after treatment, since audiometric monitoring is specifically recommended in clinical guidance for cisplatin
- Mentioning any history of significant noise exposure to your oncology team, since it's an identified risk factor that may factor into monitoring decisions
- Not assuming tinnitus during or after treatment is unrelated to the chemotherapy — it's a recognized, well-documented effect, not something to dismiss or feel you need to downplay
A trial that prevented it, and what prevention cost
Preventing cisplatin-induced tinnitus rather than managing it afterwards is the obvious ambition, and a 2026 Phase IIIB randomised trial in Ear and Hearing tested one route: dexamethasone delivered directly into the middle ear during chemotherapy, through the same intratympanic route used for sudden hearing loss.
Patients received an average cisplatin dose of 444.87 mg. The experimental group was 23 patients treated in one ear each — 46 ears, 23 treated and 23 untreated — against a control group of 20 ears receiving none.
The benefit. After treatment, no patient in the experimental group reported tinnitus in either ear. Among patients given no dexamethasone at all, bilateral tinnitus appeared in 90%, with a mean worsening of 20.2 points on the Tinnitus Handicap Inventory. Hearing thresholds were not affected by the treatment.
The cost. Delivering a high dose over an extended period required a device in the eardrum:
- 8.69% had infection complications during treatment
- 34.8% had a permanent perforation of the eardrum six months after the device was removed
Read both together, because either alone misleads. Taking tinnitus from 90% to none is a striking result. Leaving roughly one in three people with a permanent hole in the eardrum is not a minor intervention — a perforation carries its own consequences for hearing, for keeping water out of the ear, and sometimes for further surgery to repair it.
One detail deserves a second look. Protection extended to the untreated ear in those same patients, which a purely local drug effect does not explain. That points toward systemic absorption from the middle ear rather than a contained local action — an interesting result, and one that needs replicating before the mechanism is treated as settled.
This is a single trial with modest numbers. What it establishes is that cisplatin-induced tinnitus is preventable in principle, which is more than could be said before. What it does not establish is that this particular delivery method is the version anyone should end up using.
What was tried before, and why prevention is a harder problem than it looks
The 2026 trial above is striking partly because of what came before it. A Cochrane review of medical interventions to prevent platinum-induced hearing loss in children, updated in 2019, found two randomised trials and one controlled trial, 149 participants in total, evaluating amifostine against no additional treatment. Pooling was not possible. The effects on ototoxicity were uncertain on low-certainty evidence. Only a single randomised trial evaluated sodium thiosulfate, in children with localised hepatoblastoma.
Its conclusion is careful: there is no evidence supporting amifostine as an otoprotective intervention, and no definitive conclusions can be drawn. It ends with a principle worth keeping in mind whenever a treatment is unproven — "no evidence of effect" is not the same as "evidence of no effect."
The other agent people ask about is N-acetylcysteine, sold widely as a hearing-protection supplement and plausible on mechanism — it supports the cochlea's defence against oxidative stress. A 2025 systematic review and meta-analysis in Otolaryngology–Head and Neck Surgery pooled seven studies and 217 patients and tested it properly:
- Systemic NAC against placebo — risk ratio 0.80 (95% CI 0.54–1.19), P = .28
- Transtympanic NAC against placebo — 0.89 (0.51–1.54), P = .67
Neither significant, and no difference anywhere across the 0.5–8 kHz standard audiogram range. A qualitative tendency toward protection appeared at ultra-high frequencies, 10 and 12 kHz, which is above what a standard audiogram tests and was not a significant pooled effect. The authors conclude the published evidence does not show NAC is effective. Whether any pill protects hearing covers the wider question.
Put the three together and the shape of the problem is clear. Preventing platinum ototoxicity has been attempted for years with systemic protective agents, and the pooled evidence for those is thin and uncertain. The 2026 trial took a different route — delivering the drug into the ear rather than the bloodstream — and got a far more dramatic result, at a cost of one in three eardrums.
That is progress with a price attached rather than a solved problem, and it is the honest position to hold until somebody replicates it with a delivery method that does not leave a hole.
Thirteen studies, 2,837 children, and nobody wrote the tinnitus down
A separate Cochrane review asked how common hearing loss is after platinum chemotherapy in childhood. It found 13 cohort studies covering 2,837 participants who had a hearing test after treatment.
The prevalence it found ranged from 0% to 90.1%.
That is not a typo, and narrowing to the studies that bothered to define hearing loss only moves the bottom of the range to 1.7%. The studies differed in how they defined hearing loss, which tests they used, which patients they included, what other ototoxic drugs were given and how long they followed people for — so pooling was impossible. In the two studies that had a control group at all, one reported 67.1% (95% CI 59.3–74.1) in platinum-treated participants.
And this sentence, which is the reason it appears on this page: "none of the studies provided data on tinnitus".
Thirteen studies. Nearly three thousand children. Every one of them given a hearing test after treatment with a drug known to damage the ear — and not one recorded whether the children had ringing.
That absence is the honest answer to "how common is tinnitus after childhood platinum chemotherapy", and it is worth stating rather than substituting the hearing-loss figures for it. Hearing loss and tinnitus travel together but they are not the same measurement, and quoting one as though it were the other would mislead.
What the review does recommend is screening: children treated with platinum analogues should be checked for ototoxicity so hearing loss is caught early. It declines to specify a follow-up protocol, because the evidence does not support one.
Managing tinnitus after cisplatin
If you're a cancer survivor who received cisplatin and have tinnitus, you're not alone in that combination — in the survivor studies above, most patients reported it — and it's a legitimate topic to raise with both your oncology team and an audiologist. The same management approaches apply as for any persistent tinnitus: sound therapy, CBT, and hearing aids where there is hearing loss. The underlying cause being chemotherapy doesn't change what helps manage the tinnitus itself.